Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · IEX Real-Time Price · USD
7.23
-0.02 (-0.28%)
May 17, 2024, 4:30 PM EDT - Market closed
Nanobiotix Revenue
In the year 2023, Nanobiotix had annual revenue of $40.23M with 691.80% growth.
Revenue (ttm)
$40.23M
Revenue Growth
+691.80%
P/S Ratio
8.42
Revenue / Employee
$394,412
Employees
102
Market Cap
338.73M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 40.23M | 35.15M | 691.80% |
Dec 31, 2022 | 5.08M | 2.07M | 68.91% |
Dec 31, 2021 | 3.01M | -55.46K | -1.81% |
Dec 31, 2020 | 3.06M | 208.36K | 7.30% |
Dec 31, 2019 | 2.86M | -1.14M | -28.60% |
Dec 31, 2018 | 4.00M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNBTX News
- 3 days ago - NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 - GlobeNewsWire
- 4 days ago - NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer - GlobeNewsWire
- 24 days ago - NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 - GlobeNewsWire
- 6 weeks ago - Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation - GlobeNewsWire
- 2 months ago - Nanobiotix to Present at Upcoming Investor Conferences in March - GlobeNewsWire
- 3 months ago - Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference - GlobeNewsWire
- 3 months ago - Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study - GlobeNewsWire